PL2459555T3 - Sposoby krystalizacji rywaroksabanu - Google Patents
Sposoby krystalizacji rywaroksabanuInfo
- Publication number
- PL2459555T3 PL2459555T3 PL10740170T PL10740170T PL2459555T3 PL 2459555 T3 PL2459555 T3 PL 2459555T3 PL 10740170 T PL10740170 T PL 10740170T PL 10740170 T PL10740170 T PL 10740170T PL 2459555 T3 PL2459555 T3 PL 2459555T3
- Authority
- PL
- Poland
- Prior art keywords
- rivaroxaban
- crystallization
- processes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200900218 | 2009-07-31 | ||
PCT/EP2010/004688 WO2011012321A1 (en) | 2009-07-31 | 2010-07-30 | Processes for crystallization of rivaroxaban |
EP10740170.5A EP2459555B1 (en) | 2009-07-31 | 2010-07-30 | Processes for crystallization of rivaroxaban |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2459555T3 true PL2459555T3 (pl) | 2022-03-28 |
Family
ID=42831508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL10740170T PL2459555T3 (pl) | 2009-07-31 | 2010-07-30 | Sposoby krystalizacji rywaroksabanu |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2459555B1 (pl) |
EA (1) | EA031064B2 (pl) |
ES (1) | ES2905760T3 (pl) |
HU (1) | HUE057769T2 (pl) |
PL (1) | PL2459555T3 (pl) |
SI (1) | SI2459555T1 (pl) |
WO (1) | WO2011012321A1 (pl) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD4557C1 (ro) * | 2011-05-06 | 2018-10-31 | Egis Gyogysszegyar Nyilvanosan Mukodo Reszvenytarsasag | Procedeu de obţinere a rivaroxabanului şi un compus intermediar utilizat în acest procedeu |
CN102827154B (zh) * | 2011-06-14 | 2015-04-22 | 上海科胜药物研发有限公司 | 一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法 |
CN103012388B (zh) * | 2011-09-20 | 2016-01-20 | 联化科技(上海)有限公司 | 一种利伐沙班及其中间体的制备方法,以及中间体化合物 |
EP2573084A1 (en) * | 2011-09-22 | 2013-03-27 | Enantia, S.L. | Novel crystalline forms of rivaroxaban and processes for their preparation |
US9376427B2 (en) | 2012-05-02 | 2016-06-28 | Symed Labs Limited | Process for preparing rivaroxaban using intermediates |
WO2014020458A1 (en) * | 2012-08-01 | 2014-02-06 | Alembic Pharmaceuticals Limited | Improved process for preparation of rivaroxaban |
EP2935255B1 (en) | 2012-12-21 | 2017-08-16 | Farma GRS, d.o.o. | A process for preparation of rivaroxaban |
WO2014102822A2 (en) | 2012-12-26 | 2014-07-03 | Wanbury Ltd. | Aldehyde derivative of substitute oxazolidinones |
DK2895176T3 (en) | 2012-12-26 | 2017-01-30 | Wanbury Ltd | RIVAROXABAN INTERMEDIATE PRODUCTS AND MANUFACTURING THEREOF |
WO2014155259A2 (en) * | 2013-03-25 | 2014-10-02 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for the preparation of rivaroxaban |
CN104109158A (zh) * | 2013-04-16 | 2014-10-22 | 上海医药工业研究院 | 一种纯化利伐沙班的方法 |
CN104650058A (zh) * | 2013-11-23 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 利伐沙班一水合物化合物 |
IN2014MU00072A (pl) | 2014-01-08 | 2015-08-21 | Wockhardt Ltd | |
IN2014CH00290A (pl) * | 2014-01-23 | 2015-08-14 | Symed Labs Ltd | |
WO2015198259A1 (en) | 2014-06-26 | 2015-12-30 | Erregierre S.P.A. | Process for the synthesis of rivaroxaban and intermediate for the production thereof |
CN104211693B (zh) * | 2014-08-07 | 2017-02-22 | 成都百裕制药股份有限公司 | 一种利伐沙班晶型及其制备方法与用途 |
CN105503849B (zh) * | 2014-09-26 | 2019-10-08 | 重庆华邦胜凯制药有限公司 | 一种制备小粒度利伐沙班原料药的方法 |
EP3209661B1 (en) | 2014-10-22 | 2021-02-17 | Zaklady Farmaceutyczne Polpharma SA | Process for preparing a polymorph of rivaroxaban |
CN107778303B (zh) * | 2016-08-27 | 2020-03-24 | 鲁南制药集团股份有限公司 | 利伐沙班的精制方法 |
CN108344832B (zh) * | 2017-12-28 | 2021-03-09 | 江苏悦兴医药技术有限公司 | 一种主成分与其杂质完全分离的检测方法 |
CN109142601B (zh) * | 2018-10-25 | 2021-03-12 | 重庆华邦胜凯制药有限公司 | 一种分离利伐沙班中间体及其杂质的方法 |
CN111518092B (zh) * | 2019-02-01 | 2022-12-20 | 鲁南制药集团股份有限公司 | 利伐沙班乙酸溶剂合物及其制备方法 |
CN110003193B (zh) * | 2019-04-02 | 2023-12-05 | 北京四环制药有限公司 | 一种制备易于粉碎的利伐沙班及其制备方法 |
CN111721858B (zh) * | 2020-06-03 | 2022-07-01 | 杭州华东医药集团新药研究院有限公司 | 一种测定利伐沙班中基因毒性杂质的方法 |
GR1010231B (el) * | 2021-03-24 | 2022-05-10 | Φαρματεν Α.Β.Ε.Ε., | Φαρμακευτικο σκευασμα που περιλαμβανει ριβαροξαμπανη και μεθοδος παρασκευης αυτου |
EP4201933A1 (en) | 2021-12-23 | 2023-06-28 | Zaklady Farmaceutyczne Polpharma S.A. | Crystallisation process for rivaroxaban |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19962924A1 (de) * | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE10129725A1 (de) | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
DE10300111A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
DE102004002044A1 (de) | 2004-01-15 | 2005-08-04 | Bayer Healthcare Ag | Herstellverfahren |
NZ567092A (en) | 2005-10-04 | 2011-05-27 | Bayer Schering Pharma Ag | Novel polymorphous form and the amorphous form of 5-chloro-N-({ (5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide |
BRPI0820964A2 (pt) * | 2007-12-11 | 2015-07-14 | Bayer Schering Pharma Ag | Oxazolidinonas para o tratamento e/ou profilaxia de insuficiência cardíaca |
US20100168111A1 (en) | 2008-12-31 | 2010-07-01 | Apotex Pharmachem Inc. | Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide |
WO2014020458A1 (en) | 2012-08-01 | 2014-02-06 | Alembic Pharmaceuticals Limited | Improved process for preparation of rivaroxaban |
-
2010
- 2010-07-30 SI SI201032103T patent/SI2459555T1/sl unknown
- 2010-07-30 EA EA201290074A patent/EA031064B2/ru active IP Right Maintenance
- 2010-07-30 WO PCT/EP2010/004688 patent/WO2011012321A1/en active Application Filing
- 2010-07-30 HU HUE10740170A patent/HUE057769T2/hu unknown
- 2010-07-30 ES ES10740170T patent/ES2905760T3/es active Active
- 2010-07-30 EP EP10740170.5A patent/EP2459555B1/en active Active
- 2010-07-30 PL PL10740170T patent/PL2459555T3/pl unknown
Also Published As
Publication number | Publication date |
---|---|
EA031064B2 (ru) | 2020-07-01 |
EP2459555B1 (en) | 2021-11-03 |
HUE057769T2 (hu) | 2022-06-28 |
SI2459555T1 (sl) | 2022-03-31 |
ES2905760T3 (es) | 2022-04-12 |
EP2459555A1 (en) | 2012-06-06 |
WO2011012321A1 (en) | 2011-02-03 |
EA031064B1 (ru) | 2018-11-30 |
EA201290074A1 (ru) | 2012-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2459555T3 (pl) | Sposoby krystalizacji rywaroksabanu | |
IL283038A (en) | Processes for preparing intermediates for protein tyrosine kinase inhibitors | |
HK1254977A1 (zh) | 索非布韋(sofosbuvir)的結晶形式 | |
ZA201600646B (en) | Process for beta-lactone production | |
PL2634191T3 (pl) | Sposób wytwarzania pochodnych tienopirymidynodionu | |
EP2480523A4 (en) | PROCESS FOR THE PRODUCTION OF N-ACYLBPHENYLALANINE | |
EP2439312A4 (en) | PROCESS FOR PRODUCING REDUCED GLUTATHION | |
EP2407461A4 (en) | PROCESS FOR PREPARING 1-ALKYL-5-BENZOYL-1H-TETRAZOL DERIVATIVES | |
IL216942A0 (en) | Process for the manufacture of alkenones | |
ZA201202343B (en) | Process for the preparation of lenalidomide | |
EP2292579A4 (en) | PROCESS FOR THE PRODUCTION OF HALOGENATED FLUOROETHERS | |
EP2400848A4 (en) | CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS | |
ZA201109045B (en) | Crystalline form of pemirolast | |
EP2514719A4 (en) | PROCESS FOR SYNTHESIS OF AMMONIA | |
EP2423187A4 (en) | PROCESS FOR PRODUCING N-ALCOXYCARBONYL-tert-LEUCINS | |
EP2491044A4 (en) | IMPROVED METHOD FOR THE PREPARATION OF CLOPIODOGREL BISULFATE IN THE CRYSTAL FORM 1 | |
EP2511234A4 (en) | PROCESS FOR THE PRODUCTION OF DDR ZEOLITE | |
EP2514783A4 (en) | METHOD FOR PRODUCING AN ORGANOPOLYSILOXAN COMPOUND | |
EP2423212A4 (en) | PROCESS FOR PREPARING A 2-AZAADAMANTAN COMPOUND FROM A BICYCLOCARBAMATE COMPOUND | |
EP2281780A4 (en) | PROCESS FOR PREPARING SILICON | |
EP2251329A4 (en) | PROCESS FOR THE PRODUCTION OF 3-AMINO-2-CHLORO-6-TRIFLUOROMETHYLPYRIDINE | |
GB0906289D0 (en) | Processes for making isoxazoline derivatives | |
EP2514784A4 (en) | PROCESS FOR THE PRODUCTION OF ORGANOPOLYSILOXANE COMPOUND | |
GB0913427D0 (en) | Compounds for treatment of imflammation | |
EP2514302A4 (en) | PROCESS FOR PRODUCING MULTI-PETAL CYCLAMEN |